Mark M. Awad, MD, PhD, discusses the characterization of patients with non–small cell lung cancer who have MET exon 14 skipping alterations and potential acquired resistance mechanisms.
Mark M. Awad, MD, PhD, clinical director of the Thoracic Oncology Treatment Center at Dana-Farber Cancer Institute and assistant professor of Medicine at Harvard Medical School, discusses the characterization of patients with non–small cell lung cancer (NSCLC) who have MET exon 14 (METex14) skipping alterations (SA) and potential acquired resistance mechanisms.
In this study, which was done in collaboration with Foundation Medicine, over 60,000 patients with NSCLC were investigated and 1387 (2.3), had METex14 mutations. Awad says this is an important and emerging subset of lung cancer to identify, especially now since there is an FDA-approved targeted therapy called capmatinib (Trabrecta) for patients with METex14 SA.
Since this is a relatively new target in the lung cancer setting, it is more important to identify the characteristics of these cancers to see what other mutations may be present within the genome as much as possible, according to Awad. The trial also looked to answer whether there are other factors that may regulate response or resistance to either immunotherapy or to targeted therapy.
<< View more of Targeted Oncology's coverage from the 2020 ASCO Virtual Annual Meeting
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More